Gadobutrol Magnevist-controlled Body Study

Inclusion Criteria: * Is at least 20 years of age * Is referred for a contrast-enhanced MRI of the body/extremities based on current clinical symptoms or results of a previous imaging procedure * Is willing to undergo the routine contrast-enhanced MRI examinations * Is willing and able to complete all study procedures specified in the protocol * Subject is male, or is female not of childbearing potential, or is female of childbearing potential who is using any medically accepted means of contraception and has a negative urine pregnancy test prior to the administration of gadobutrol or Magnevist Exclusion Criteria: * Is a female subject who is pregnant or nursing * Has received any investigational product or has participated in any other clinical trial within 2 weeks prior to enrolling in this study * Has been previously enrolled in this study or any other study using gadobutrol * Has any contraindication to the MRI examinations or the use of Gd-containing contrast agents * Has a history of severe allergic or anaphylactoid reaction to any allergen including drugs and contrast agents * Has received any contrast agent within 24 hours prior to the study MRI * Has a glomerular filtration rate value \<30 mL/min/1.73m2 derived from a serum creatinine result within 4 weeks prior to study enrollment * Is considered clinically unstable or his/her clinical course during the study period is unpredictable (eg, due to previous surgery, acute renal failure) * Has severe cardiovascular disease (eg, acute myocardial infarction (\<14 days), unstable angina, congestive heart failure New York Heart Association class IV) or acute stroke (\<48 hours) * Patients with acute renal insufficiency of any severity due to hepato-renal syndrome or in the perioperative liver transplantation period * Has any contraindication to Magnevist according to the package insert